Author

Daniela Pugliese 1

1 Università Cattolica del S

Are we choosing wisely in inflammatory bowel disease care? The IG-IBD choosing wisely campaign

Marco Vincenzo Lenti, Alessandro Armuzzi, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, Ambrogio Orlando, Daniela Pugliese, Fernando Rizzello, Maurizio Vecchi, Antonio Di Sabatino

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

COMBINATION THERAPY PREDICTS LONG-TERM MUCOSAL HEALING IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH ANTI TNF-?

Daniela Pugliese, Pietro Manuel Ferraro, Carla Felice, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino, Anna Viola, Davide Giuseppe Ribaldone, Andrea Buda, Cristina Bezzio, Gionata Fiorino, Massimo Claudio Fantini, Franco Scaldaferri, Luisa Guidi, Silvio Danese, Antonio Gasbarrini, Ambrogio Orlando, Alessandro Armuzzi

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Ahmad Albshesh, Joshua Taylor, Edoardo Vincenzo Savarino, Marie Truyens, Alessandro Armuzzi, Davide Giuseppe Ribaldone, Ariella Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancy, Mohamed Korani, Klaudia Farkas, Manuel Barreiro de Acosta, Viktor Domislovic, Gerard Surís, Carl Eriksson, Catarin

HISTOLOGICAL FEATURES OF JOINT AND COLONIC INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNFA

Stefano Alivernini, Daniela Pugliese, Barbara Tolusso, Luca Petricca, Laura Bui, Luisa Guidi, Gian Lodovico Rapaccini, Francesco Federico, Gianfranco Ferraccioli, Alessandro Armuzzi, Elisa Gremese

INFLIXIMAB LEVEL AND ANTI-DRUG ANTIBODY IN INFLAMMATORY BOWEL DISEASE PATIENTS LOSING RESPONSE: ASSAY AFTER OPTIMIZATION AND OUTCOME AT ONE YEAR.

Luisa Guidi, Manuela Marzo, Barbara Tolusso, Daniela Pugliese, Gianluca Andrisani, Carla Felice, Rosario Landi, Silvia Canestri, Elisa Gremese, Italo De Vitis, Alfredo Papa, Gian Lodovico Rapaccini, Alessandro Armuzzi

ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Daniela Pugliese, Giuseppe Privitera, Alessandro Armuzzi

Item 1 - 10 / 24
1
2 3